| BID | 0.3800 | ASK | 0.4000 | ||
| Open | 0.3850 | Previous Close | 0.3850 | ||
| Pre-Market | - | After-Market | 0.40 | ||
| - - | 0.01 2.05% |
| Target Price | 9.00 | Analyst Rating | Hold 3.00 | |
| Potential % | 2.21K | Finscreener Ranking | ★+ 43.58 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★ 40.22 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★ 34.59 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 19.05 | Earnings Rating | Buy | |
| Market Cap | 14.32M | Earnings Date | 30th Mar 2023 | |
| Alpha | -0.02 | Standard Deviation | 0.29 | |
| Beta | 1.69 |
Today's Price Range 0.38000.4000 | 52W Range 0.19001.24 | 5 Year PE Ratio Range -9.30-6.50 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 11.43% | ||
| 1 Month | -11.98% | ||
| 3 Months | 76.15% | ||
| 6 Months | 6.85% | ||
| 1 Year | -55.86% | ||
| 3 Years | -92.02% | ||
| 5 Years | -95.06% | ||
| 10 Years | -92.88% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -58.63 | |||
ROE last 12 Months | -124.72 | |||
ROA (5Y Avg) | -23.79 | |||
ROA last 12 Months | -54.60 | |||
ROC (5Y Avg) | -34.15 | |||
ROC last 12 Months | -62.04 | |||
Return on invested Capital Q | -14.96 | |||
Return on invested Capital Y | -20.06 | |||
Assets Turnover | 0.60 | |||
Receivables Turnover | 5.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.20 | ||||
| 0.56 | ||||
| 0.26 | ||||
| 649.30 | ||||
| -0.90 | ||||
| -0.54 | ||||
| 0.56 | ||||
| 0.48 | ||||
| 14.66M | ||||
| Forward PE | -0.27 | |||
| PEG | -0.03 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.70 | ||||
| 1.20 | ||||
| 0.24 | ||||
| 1.45 | ||||
| -17.20 | ||||
| Leverage Ratio | 2.80 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 8.60 | ||||
| -57.60 | ||||
| -53.00 | ||||
| -51.30 | ||||
| -57.27 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 39.18M | ||||
| 1.07 | ||||
| 5.11 | ||||
| 13.46 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2022 | - | -0.21 | - |
| Q02 2022 | - | -0.23 | - |
| Q01 2022 | - | -0.29 | - |
| Q04 2021 | -0.23 | -0.32 | -39.13 |
| Q03 2021 | -0.21 | -0.23 | -9.52 |
| Q02 2021 | -0.38 | -0.35 | 7.89 |
| Q01 2021 | -0.30 | -0.22 | 26.67 |
| Q04 2020 | - | -0.35 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2020 QR | -0.33 | 0.00 | - |
| 3/2022 QR | -0.37 | 66.06 | Positive |
| 12/2022 FY | -1.36 | - | - |
| 12/2023 FY | -1.27 | - | - |
| Next Report Date | 30th Mar 2023 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 521.26K |
| Shares Outstanding | 36.73K |
| Shares Float | 29.79M |
| Trades Count | 727 |
| Dollar Volume | 201.33K |
| Avg. Volume | 673.52K |
| Avg. Weekly Volume | 806.65K |
| Avg. Monthly Volume | 549.31K |
| Avg. Quarterly Volume | 664.60K |
Chembio Diagnostics Inc. (NASDAQ: CEMI) stock closed at 0.39 per share at the end of the most recent trading day (a 1.3% change compared to the prior day closing price) with a volume of 521.26K shares and market capitalization of 14.32M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 324 people. Chembio Diagnostics Inc. CEO is Richard L. Eberly.
The one-year performance of Chembio Diagnostics Inc. stock is -55.86%, while year-to-date (YTD) performance is 77.51%. CEMI stock has a five-year performance of -95.06%. Its 52-week range is between 0.19 and 1.24, which gives CEMI stock a 52-week price range ratio of 19.05%
Chembio Diagnostics Inc. currently has a PE ratio of -0.20, a price-to-book (PB) ratio of 0.56, a price-to-sale (PS) ratio of 0.26, a price to cashflow ratio of 649.30, a PEG ratio of 2.32, a ROA of -54.60%, a ROC of -62.04% and a ROE of -124.72%. The company’s profit margin is -57.27%, its EBITDA margin is -53.00%, and its revenue ttm is $39.18 Million , which makes it $1.07 revenue per share.
Of the last four earnings reports from Chembio Diagnostics Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Chembio Diagnostics Inc.’s next earnings report date is 30th Mar 2023.
The consensus rating of Wall Street analysts for Chembio Diagnostics Inc. is Hold (3), with a target price of $9, which is +2 207.69% compared to the current price. The earnings rating for Chembio Diagnostics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Chembio Diagnostics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Chembio Diagnostics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 23.03, ATR14 : 0.02, CCI20 : -49.72, Chaikin Money Flow : 0.06, MACD : -0.01, Money Flow Index : 54.42, ROC : -12.67, RSI : 45.63, STOCH (14,3) : 55.16, STOCH RSI : 1.00, UO : 40.94, Williams %R : -44.84), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Chembio Diagnostics Inc. in the last 12-months were:
Chembio Diagnostics Inc.
Chembio Diagnostics Inc is a US-based company that develops, manufactures, and commercializes point-of-care diagnostic tests that detect infectious diseases. The products of the company include rapid tests for the detection of HIV 1/2 antibodies and a multiplex rapid test for the detection of HIV and syphilis antibodies. The company offered rapid medical tests that are offered in Africa, Asia, Europe, and the Middle East, Latin America and the United States, of which key revenue is derived from Latin America.
CEO: Richard L. Eberly
Telephone: +1 631 924-1135
Address: 555 Wireless Boulevard, Hauppauge 11788, NY, US
Number of employees: 324
